- Home
- CHRS vs IDR Comparison
CHRS vs IDR Comparison
Compare CHRS & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- IDR
- Stock Information
- Founded
- CHRS 2010
- IDR 1996
- Country
- CHRS United States
- IDR United States
- Employees
- CHRS 235
- IDR N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- IDR Precious Metals
- Sector
- CHRS Health Care
- IDR Basic Materials
- Exchange
- CHRS Nasdaq
- IDR Nasdaq
- Market Cap
- CHRS 134.4M
- IDR 142.7M
- IPO Year
- CHRS 2014
- IDR N/A
- Fundamental
- Price
- CHRS $1.16
- IDR $13.65
- Analyst Decision
- CHRS Strong Buy
- IDR Strong Buy
- Analyst Count
- CHRS 4
- IDR 1
- Target Price
- CHRS $5.38
- IDR $14.00
- AVG Volume (30 Days)
- CHRS 2.4M
- IDR 142.6K
- Earning Date
- CHRS 03-12-2025
- IDR 03-24-2025
- Dividend Yield
- CHRS N/A
- IDR N/A
- EPS Growth
- CHRS N/A
- IDR 344.27
- EPS
- CHRS N/A
- IDR 0.52
- Revenue
- CHRS $304,340,000.00
- IDR $21,955,008.00
- Revenue This Year
- CHRS $2.47
- IDR $86.37
- Revenue Next Year
- CHRS N/A
- IDR $11.11
- P/E Ratio
- CHRS N/A
- IDR $26.67
- Revenue Growth
- CHRS 44.19
- IDR 64.93
- 52 Week Low
- CHRS $0.66
- IDR $6.40
- 52 Week High
- CHRS $2.87
- IDR $18.35
- Technical
- Relative Strength Index (RSI)
- CHRS 38.01
- IDR 62.01
- Support Level
- CHRS $1.03
- IDR $12.46
- Resistance Level
- CHRS $1.39
- IDR $13.40
- Average True Range (ATR)
- CHRS 0.14
- IDR 0.65
- MACD
- CHRS -0.03
- IDR 0.22
- Stochastic Oscillator
- CHRS 14.04
- IDR 80.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.